Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › SUSTAIN-6

SUSTAIN-6

Semaglutide · T2D at high CV risk

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Semaglutide
Population
T2D at high CV risk
Official title
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
Sponsor
Novo Nordisk A/S
Phase
Phase 3
Registry status
completed · 2013-02 → 2016-03
Participants
3297
Registry
NCT01720446

Cardiovascular and kidney outcomes

SUSTAIN-6 semaglutide 0.5/1.0 mg vs placebo · T2D at high CV risk · n = 3297 · 2016 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE primary
First occurrence of CV death, nonfatal MI (including silent), or nonfatal stroke
0.740.58–0.95108 vs 146verified
Cardiovascular death
Death from cardiovascular causes
0.980.65–1.4844 vs 46verified
All-cause death
Death from any cause
1.050.74–1.5062 vs 60verified
Myocardial infarction
Nonfatal myocardial infarction only (fatal MI not reported separately)
0.740.51–1.0847 vs 64verified
Stroke
Nonfatal stroke only (fatal stroke not reported separately)
0.610.38–0.9927 vs 44verified
Hospitalisation for heart failure
Hospitalization for heart failure
1.110.77–1.6159 vs 54verified
Kidney composite
New or worsening nephropathy: persistent macroalbuminuria, persistent doubling of serum creatinine with creatinine clearance <45 ml/min/1.73 m2 (MDRD), or need
0.640.46–0.8862 vs 100verified
Expanded MACE (MACE + HF hosp. + revasc. + UA)
Expanded composite: death from CV causes, nonfatal MI, nonfatal stroke, revascularization (coronary or peripheral), and hospitalization for unstable angina or heart failure
0.740.62–0.89199 vs 264verified
Retinopathy complications
Diabetic retinopathy complications: vitreous hemorrhage, onset of diabetes-related blindness, or need for treatment with an intravitreal agent or retinal photocoagulation
1.761.11–2.7850 vs 29verified
Coronary revascularisation
Revascularization (coronary or peripheral; not coronary-only)
0.650.50–0.8683 vs 126verified
Hospitalisation for unstable angina
Hospitalization for unstable angina pectoris
0.820.47–1.4422 vs 27verified
Verbatim quotes (11)
  • 3-point MACE · Results, Cardiovascular Outcomes, paragraph 1; Table 2
    The composite primary outcome occurred in 108 of 1648 patients (6.6%) in the semaglutide group and 146 of 1649 (8.9%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.58 to 0.95
  • Cardiovascular death · Results, Cardiovascular Outcomes, paragraph 1; Table 2
    deaths reported in 44 patients (2.7%) in the semaglutide group and 46 (2.8%) in the placebo group (hazard ratio, 0.98; 95% CI, 0.65 to 1.48; P = 0.92)
  • All-cause death · Table 2
    From any cause 62 (3.8) 1.82 60 (3.6) 1.76 1.05 (0.74–1.50) 0.79
  • Myocardial infarction · Results, Cardiovascular Outcomes, paragraph 1; Table 2
    Nonfatal myocardial infarction occurred in 47 patients (2.9%) in the semaglutide group and 64 (3.9%) in the placebo group (hazard ratio, 0.74; 95% CI, 0.51 to 1.08; P = 0.12)
  • Stroke · Results, Cardiovascular Outcomes, paragraph 1; Table 2
    Nonfatal stroke occurred in 27 patients (1.6%) in the semaglutide group and 44 (2.7%) in the placebo group (hazard ratio, 0.61; 95% CI, 0.38 to 0.99; P = 0.04)
  • Hospitalisation for heart failure · Table 2
    Hospitalization for heart failure 59 (3.6) 1.76 54 (3.3) 1.61 1.11 (0.77–1.61) 0.57
  • Kidney composite · Results, Microvascular Outcomes; Table 2
    New or worsening nephropathy occurred in 62 patients (3.8%) in the semaglutide group and 100 (6.1%) in the placebo group (hazard ratio, 0.64; 95% CI, 0.46 to 0.88; P = 0.005)
  • Expanded MACE (MACE + HF hosp. + revasc. + UA) · Table 2
    Expanded composite outcome‡ 199 (12.1) 6.17 264 (16.0) 8.36 0.74 (0.62–0.89)
  • Retinopathy complications · Table 2
    Retinopathy complications§ 50 (3.0) 1.49 29 (1.8) 0.86 1.76 (1.11–2.78)
  • Coronary revascularisation · Table 2
    Revascularization 83 (5.0) 2.50 126 (7.6) 3.85 0.65 (0.50–0.86)
  • Hospitalisation for unstable angina · Table 2
    Hospitalization for unstable angina pectoris 22 (1.3) 0.65 27 (1.6) 0.80 0.82 (0.47–1.44)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: SUSTAIN-6. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/sustain-6/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.